Belfast Trust licenses patent to HiberGene Diagnostics
HSC Innovations is pleased to announce that Belfast Health and Social Care Trust has licensed its novel rapid meningitis diagnostic test to HiberGene Diagnostics Ltd, a start-up client company of NovaUCD, the Innovation and Technology Transfer Centre, Dublin, Ireland. The licence grants HiberGene exclusive rights to commercialise the product worldwide.
Diagnosis of meningitis is notoriously difficult, with ambiguous flu-like symptoms initially, which make early diagnosis very challenging. Standard laboratory tests take at least 24 hours, and there is a need for rapid, sensitive and specific tests to allow earlier confirmation of the diagnosis and earlier treatment.
The new test, which provides a reliable diagnosis in less than one hour, was developed by scientists in the Royal Victoria Hospital laboratories. The test uses an emerging molecular method known as loop-mediated isothermal amplification (LAMP) which is a form of rapid polymerase chain reaction, to provide the result. The new test has the potential to be used in emergency departments instead of hospital laboratories and is currently being evaluated at the Royal Belfast Hospital for Sick Children.
Consultant Paediatrician Professor Mike Shields led the original research project, which was supported by grants from the Meningitis Research Foundation (MRF) to Queen’s University Belfast and the HSC R&D Division, Public Health Agency, to the Belfast Trust.
Professor Shields said, “Meningitis presents a clinical challenge for the emergency department doctor because the patient’s symptoms can be non-specific. No doctor wants to send a seriously sick child home, which is why this new diagnostic test holds such promise. When this test is available it will have the potential to save many lives.”
Linda Glennie, Head of Research and Medical Information at MRF, said, “We’re delighted that MRF’s funding has led to the development of this diagnostic test and look forward to seeing progression towards quicker diagnosis of meningitis and septicaemia.”
Brendan Farrell, CEO, HiberGene Diagnostics said, “We are particularly pleased to have secured exclusive rights to the meningitis test from the Belfast Trust. Clinical validation of the test has shown a sensitivity of 100% and a specificity of 99.7% which is excellent. HiberGene plans to commercialise the test in the first half of 2012 and is already in discussions with a number of potential distribution partners in the USA and Europe. We look forward to further collaboration with the Trust.”
HiberGene is also currently working on a series of additional molecular assays to rapidly detect pathogenic micro-organisms.
HSC Innovations, the technology transfer office for the Northern Ireland Health and Social Care service, patented the invention and facilitated the deal with HiberGene.
Professor Ian Young, Director of Research for the Belfast Trust said, “This diagnostic is an excellent example of the high-quality research that is conducted by doctors, nurses and scientists in the Belfast Trust. I am particularly pleased that HSC Innovations has secured patent protection for this diagnostic, making it an appealing proposition to a commercial partner. We look forward to the test reaching the market and improving patient care.”
Further information about the technology is available here.